期刊
VACCINE
卷 36, 期 12, 页码 1637-1642出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2018.01.069
关键词
Malaria; RTS,S; HLA; Antibody; Protection
资金
- MRC PhD Studentship in Vaccine Research [MR/J003999/1]
Although RTS,S remains the most advanced malaria vaccine, the factors influencing differences in vaccine immunogenicity or efficacy between individuals or populations are still poorly characterised. The analyses of genetic determinants of immunogenicity have previously been restricted by relatively small sample sizes from individual trials. Here we combine data from six Phase 11 RTS,S trials and evaluate the relationship between HLA allele groups and RTS,S-mediated protection in controlled human malaria infections (CHMI), using multivariate logistic or linear regression. We observed significant associations between three allele groups (HLA-A*01, HLA-B*08, and HLA-DRB1*15/*16) and protection, while another three allele groups (HLA-A*03, HLA-B*53, and HLA-DRB1*07) were significantly associated with lack of protection. It is noteworthy that these 'protective' allele groups are thought to be at a lower prevalence in sub-Saharan African populations than in the UK or USA where these Phase II trials occurred. Taken together, the analyses presented here give an indication that HLA genotype may influence RTS,S-mediated protective efficacy against malaria infection. (C) 2018 The Authors. Published by Elsevier Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据